Skip to main content
. 2017 Jun 14;8(47):81926–81935. doi: 10.18632/oncotarget.18477

Figure 2. Impact of the type of failure on the outcome after failure of lenalidomide.

Figure 2

Survival is defined from documentation of failure to death of any cause or last-follow-up and is expressed in months. SD: stable disease, loss of HI: loss of hematologic improvement without bone marrow progression, PD: progressive disease at failure (to RAEB-2 or AML), LEN: lenalidomide.